Revenues (USD, thousands)

Cost of goods sold (USD, thousands)

Gross profit (USD, thousands)

Sales and marketing expenses (USD, thousands)

General and administrative expenses (USD, thousands)

Research and development expenses (USD, thousands)

Total operating expenses (USD, thousands)

Gain on sale of assets (USD, thousands)

Operating income (loss) (USD, thousands)

Interest expense (USD, thousands)

Investment in equity securities - unrealized gain (loss) (USD, thousands)

Other income (loss) (USD, thousands)

Income (loss) before income taxes (USD, thousands)

Income tax expense (benefit) (USD, thousands)

Net income (loss) (USD, thousands)

a9c6b1859fc028e721807bf75f2ec7e86fe0f628c5c005b901f06ffd5cdb24f1

Cash and Cash Equivalents (USD, thousands)

Accounts Receivable, Net (USD, thousands)

Inventory (USD, thousands)

Other Current Assets (USD, thousands)

Total Current Assets (USD, thousands)

Investment in Equity Securities (USD, thousands)

Property, Plant and Equipment, Net (USD, thousands)

Intangibles, Net (USD, thousands)

Goodwill (USD, thousands)

Deferred Tax Assets, Net (USD, thousands)

Other Long-Term Assets (USD, thousands)

Total Assets (USD, thousands)

Current Portion of Long-Term Debt and Other Borrowings (USD, thousands)

Accounts Payable (USD, thousands)

Accrued Expenses and Other Liabilities (USD, thousands)

Total Current Liabilities (USD, thousands)

Asset Retirement Obligations (USD, thousands)

Long-Term Debt, Net and Other Borrowings (USD, thousands)

Other Long-Term Liabilities (USD, thousands)

Total Liabilities (USD, thousands)

Common Stock (USD, thousands)

Additional Paid-in Capital (USD, thousands)

Treasury Stock at Cost (USD, thousands)

Retained Earnings (USD, thousands)

Accumulated Other Comprehensive Loss (USD, thousands)

Total Stockholders’ Equity (USD, thousands)

Total Liabilities and Stockholders’ Equity (USD, thousands)

099061dfc770fb07b1a250566610d4b218f5b85585b5d502cd0fa3e7ad81681b

Net cash provided by operating activities [USD, thousands]

Capital expenditures [USD, thousands]

Net cash (used in) provided by investing activities [USD, thousands]

Net cash used in financing activities [USD, thousands]

f96de982f635c2aa50050efba124682a2e34694c51577abf3012dab3c6de7999

Adjustments for Non-Cash Items (USD, thousands)

Stock-Based Compensation (USD, thousands)

Changes in Working Capital (USD, thousands)

Capital Expenditures (CapEx) (USD, thousands)

Proceeds from / Repayments of Debt (USD, thousands)

Share Repurchases (USD, thousands)

Dividend Payments (USD, thousands)

Net Change in Cash (USD, thousands)

9696f8fb87efeb8b7dae33a6d4a56dc3ae987de2e0a540662befa3dc8c215f3b

3c453d2fd65f762b10ef335231254513148cb6f273da6499d0d86a02a9d32fdc

fbda71cec35937328c272731db5fdaaffa1374cc1cb0449d5b5d80f9200b48a8

Radiopharmaceutical Oncology

- PYLARIFY

- Other Radiopharmaceutical Oncology

Precision Diagnostics

- DEFINITY

- TechneLite

- Other Precision Diagnostics

Strategic Partnerships and Other Revenue

Total Revenue

09c1fcfb54d874b560f6e7f8e5a02eb1e8b4cbf697b59812b255a6f645a405fa

Lantheus Holdings (LNTH)

Financials